Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 13Prostatic Neoplasms 7Fallopian Tube Neoplasms 5Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Glioblastoma 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1SCLC,Extensive Stage 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Carcinosarcoma 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Lung Neoplasms 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Head and Neck Neoplasms 1Glioma 1Disease Progression 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Fulvestrant 4ribociclib 2palbociclib 2Irinotecan 2Gemcitabine 2venetoclax 1tivozanib 1serabelisib 1sapanisertib 1niraparib 1lorlatinib 1liposomal doxorubicin 1inavolisib 1exemestane 1encorafenib 1cemiplimab 1binimetinib 1abemaciclib 1Taxes 1Tamoxifen 1STX-478 1Paclitaxel 1Metformin 1Lomustine 1Letrozole 1Imlunestrant 1Doxorubicin 1Cetuximab 1Carboplatin 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × niraparib × 90 days × Clear all
NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡